Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGMS NASDAQ:HOWL NASDAQ:NXTC NASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMSCyclacel Pharmaceuticals$1.06$1.01$0.73▼$23.22$5.85M-0.428,166 shs21.73 million shsHOWLWerewolf Therapeutics$0.43+1.8%$0.71$0.40▼$2.38$20.53M0.29670,917 shs209,763 shsNXTCNextCure$3.19+1.3%$9.49$2.83▼$15.74$11.38M1.394,530 shs79,604 shsVYNEVYNE Therapeutics$0.67+1.4%$0.64$0.28▼$1.96$21.88M2152,139 shs47,268 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMSCyclacel Pharmaceuticals-2.75%+10.42%+8.16%+10.41%+105,999,900.00%HOWLWerewolf Therapeutics-1.77%-13.78%-41.56%-32.00%-68.93%NXTCNextCure-7.35%-48.11%-66.35%-75.31%-44.59%VYNEVYNE Therapeutics-2.96%-3.52%+2.31%+12.62%-34.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMSCyclacel Pharmaceuticals$1.06$1.01$0.73▼$23.22$5.85M-0.428,166 shs21.73 million shsHOWLWerewolf Therapeutics$0.43+1.8%$0.71$0.40▼$2.38$20.53M0.29670,917 shs209,763 shsNXTCNextCure$3.19+1.3%$9.49$2.83▼$15.74$11.38M1.394,530 shs79,604 shsVYNEVYNE Therapeutics$0.67+1.4%$0.64$0.28▼$1.96$21.88M2152,139 shs47,268 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMSCyclacel Pharmaceuticals-2.75%+10.42%+8.16%+10.41%+105,999,900.00%HOWLWerewolf Therapeutics-1.77%-13.78%-41.56%-32.00%-68.93%NXTCNextCure-7.35%-48.11%-66.35%-75.31%-44.59%VYNEVYNE Therapeutics-2.96%-3.52%+2.31%+12.62%-34.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMSCyclacel Pharmaceuticals 1.00SellN/AN/AHOWLWerewolf Therapeutics 2.14Hold$3.75772.09% UpsideNXTCNextCure 2.20Hold$23.00621.00% UpsideVYNEVYNE Therapeutics 1.75ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest BGMS, NXTC, VYNE, and HOWL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026NXTCNextCure Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/4/2026VYNEVYNE Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/27/2026NXTCNextCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026HOWLWerewolf Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026BGMSCyclacel Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMSCyclacel Pharmaceuticals$750K7.80N/AN/A$1.40 per share0.76HOWLWerewolf Therapeutics$1.88M11.12N/AN/A$0.51 per share0.84NXTCNextCureN/AN/AN/AN/A$9.97 per shareN/AVYNEVYNE Therapeutics$570K38.91N/AN/A$0.83 per share0.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMSCyclacel Pharmaceuticals-$3M-$4.54N/AN/AN/AN/A-51.21%-44.00%N/AHOWLWerewolf Therapeutics-$60.82M-$1.24N/AN/AN/AN/A-208.23%-75.12%8/13/2026 (Estimated)NXTCNextCure-$55.84M-$17.19N/AN/AN/AN/A-186.96%-124.62%8/6/2026 (Estimated)VYNEVYNE Therapeutics-$26.48M-$0.38N/AN/AN/A-4,726.21%-70.42%-63.46%8/13/2026 (Estimated)Latest BGMS, NXTC, VYNE, and HOWL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BGMSCyclacel PharmaceuticalsN/A-$0.04N/A-$0.04N/AN/A5/15/2026Q1 2026VYNEVYNE Therapeutics-$0.18-$0.08+$0.10-$0.08$0.20 million$0.09 million5/7/2026Q1 2026HOWLWerewolf Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/A5/7/2026Q1 2026NXTCNextCure-$2.1050-$1.87+$0.2350-$1.87N/AN/A3/30/2026Q4 2025BGMSCyclacel PharmaceuticalsN/A-$2.21N/A-$2.21N/A$0.67 million3/27/2026Q4 2025HOWLWerewolf Therapeutics-$0.34-$0.20+$0.14-$0.20$0.30 millionN/A3/5/2026Q4 2025NXTCNextCure-$2.26-$0.81+$1.45-$0.81N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBGMSCyclacel PharmaceuticalsN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMSCyclacel PharmaceuticalsN/A7.065.87HOWLWerewolf TherapeuticsN/A1.271.27NXTCNextCureN/A4.614.61VYNEVYNE TherapeuticsN/A20.8620.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMSCyclacel Pharmaceuticals23.58%HOWLWerewolf Therapeutics64.84%NXTCNextCure42.65%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipBGMSCyclacel Pharmaceuticals23.75%HOWLWerewolf Therapeutics23.60%NXTCNextCure11.90%VYNEVYNE Therapeutics3.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMSCyclacel Pharmaceuticals145.52 million4.21 millionN/AHOWLWerewolf Therapeutics4048.60 million37.13 millionOptionableNXTCNextCure903.61 million3.18 millionNo DataVYNEVYNE Therapeutics3033.35 million32.34 millionNot OptionableBGMS, NXTC, VYNE, and HOWL HeadlinesRecent News About These CompaniesVYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04May 15, 2026 | msn.comShareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersDecember 18, 2025 | prnewswire.com3 penny stocks to watch now, 12/18/25December 18, 2025 | msn.comVYNE to merge with Yarrow in $200 million dealDecember 18, 2025 | thepharmaletter.comTRoundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow BioscienceDecember 17, 2025 | pharmexec.comP$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)December 17, 2025 | prnewswire.comVYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to ShareholdersDecember 17, 2025 | businesswire.comVYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks TranscriptDecember 17, 2025 | seekingalpha.comVyne Therapeutics stock soars after merger with Yarrow BioscienceDecember 17, 2025 | za.investing.comVyne Therapeutics, Yarrow Bioscience to MergeDecember 17, 2025 | marketwatch.comVyne Therapeutics shares surge on merger deal with Yarrow BioscienceDecember 17, 2025 | msn.comVYNE Therapeutics and Yarrow Bioscience Announce Merger AgreementDecember 17, 2025 | globenewswire.comVYNE Therapeutics Approves Director Elections and ProposalsDecember 12, 2025 | tipranks.comVYNE Therapeutics reports Q3 EPS (17c) vs (29c) last yearNovember 6, 2025 | msn.comVYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue EstimatesNovember 6, 2025 | zacks.comVYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business UpdateNovember 6, 2025 | globenewswire.comIncyte scraps BET inhibitor against backdrop of safety concerns for the drug classOctober 28, 2025 | fiercebiotech.comFVYNE Therapeutics (VYNE) Price Target Decreased by 22.00% to 3.32October 1, 2025 | msn.comVYNE Therapeutics Faces Nasdaq Non-Compliance NoticeSeptember 12, 2025 | msn.comVYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagAugust 19, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBGMS, NXTC, VYNE, and HOWL Company DescriptionsCyclacel Pharmaceuticals NASDAQ:BGMS$1.06 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.62 +1.56 (+147.55%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.Werewolf Therapeutics NASDAQ:HOWL$0.43 +0.01 (+1.78%) Closing price 04:00 PM EasternExtended Trading$0.43 +0.00 (+0.93%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.NextCure NASDAQ:NXTC$3.19 +0.04 (+1.27%) Closing price 04:00 PM EasternExtended Trading$3.35 +0.16 (+4.98%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.VYNE Therapeutics NASDAQ:VYNE$0.67 +0.01 (+1.39%) Closing price 04:00 PM EasternExtended Trading$0.66 0.00 (-0.32%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
